EZH2, a histone methyltransferase catalyzing H3K27 trimethylation (H3K27me3), has been shown to promote stemness, EMT and Sunitinib resistance in ccRCC and other tumors (42–44). Here, EZH2 is linked to nonpapillary renal cell carcinoma.